Zacks: Analysts Expect Vaxart Inc (NASDAQ:VXRT) to Post -$0.13 Earnings Per Share

Share on StockTwits

Wall Street brokerages expect Vaxart Inc (NASDAQ:VXRT) to report earnings per share of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Vaxart’s earnings. Vaxart reported earnings per share of ($0.66) in the same quarter last year, which would indicate a positive year over year growth rate of 80.3%. The business is expected to issue its next quarterly earnings report on Wednesday, February 5th.

According to Zacks, analysts expect that Vaxart will report full-year earnings of ($0.66) per share for the current year. For the next financial year, analysts anticipate that the company will report earnings of ($0.22) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that follow Vaxart.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. The business had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.44 million. Vaxart had a negative return on equity of 115.71% and a negative net margin of 222.20%.

A number of brokerages recently issued reports on VXRT. ValuEngine cut Vaxart from a “buy” rating to a “hold” rating in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Vaxart in a report on Monday, November 18th. Finally, Zacks Investment Research raised Vaxart from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a report on Thursday, November 21st.

In related news, major shareholder Armistice Capital Master Fund acquired 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were acquired at an average price of $0.35 per share, with a total value of $70,000.00. Corporate insiders own 7.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Sabby Management LLC raised its holdings in shares of Vaxart by 30.1% in the 3rd quarter. Sabby Management LLC now owns 1,197,710 shares of the biotechnology company’s stock valued at $430,000 after acquiring an additional 277,063 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Vaxart by 120.9% in the 2nd quarter. Renaissance Technologies LLC now owns 739,653 shares of the biotechnology company’s stock valued at $496,000 after acquiring an additional 404,883 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Vaxart by 65.4% in the 2nd quarter. Vanguard Group Inc. now owns 89,209 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 35,283 shares in the last quarter. 55.65% of the stock is currently owned by hedge funds and other institutional investors.

VXRT traded down $0.01 during trading on Friday, reaching $0.39. 243,321 shares of the company were exchanged, compared to its average volume of 422,210. The company’s 50-day moving average is $0.33 and its two-hundred day moving average is $0.48. The company has a market cap of $19.33 million, a price-to-earnings ratio of -0.15 and a beta of 0.63. The company has a quick ratio of 2.32, a current ratio of 2.32 and a debt-to-equity ratio of 0.09. Vaxart has a 12-month low of $0.25 and a 12-month high of $5.00.

About Vaxart

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Featured Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Vaxart (VXRT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.

Leave a Reply